scout

Authors

Nicole J. Mccarthy, MBBS
Latest Article

Update on Adjuvant Chemotherapy for Early Breast Cancer

Adjuvant chemotherapy represents a significant advance in the management of early-stage breast cancer and, as such, has saved many lives. Worldwide, adjuvant chemotherapy has benefitted all groups tested, including

Nicole Kounalakis, MD
Latest Article

Breast Cancer Following Radiation for Hodgkin Lymphoma: Clinical Scenarios and Risk-Reducing Strategies

We review available strategies for screening and risk reduction through chemoprevention or risk-reducing surgery, as well as challenges for management of breast cancer in patients with prior exposure to radiation for Hodgkin lymphoma.

Nicole Lamanna, MD
Latest Article

Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Kinase Inhibitors

Given the favorable results seen thus far, there is no doubt that the treatment of patients with chronic lymphocytic leukemia is entering an exciting new era with the advent of these novel, relatively nontoxic and nonmyelosuppressive, oral agents.

Nicole M. Kuderer, MD
Latest Article

CYP2D6 Testing in Breast Cancer: Ready for Prime Time?

This article will review and summarize the current data regarding the influence of the major cytochrome P450 2D6 (CYP2D6) genotypes and CYP2D6 inhibitors on tamoxifen metabolism and clinical efficacy. We will discuss the clinical relevance and limitations of this data and how to best incorporate our current understanding of CYP2D6 genotyping into our clinical practice and discussions with patients.

Nicole Renée, PhD
Latest Article

Impact of UFT on Tumoral TS and DPD Levels in Colorectal Cancer

This was an open lable, pilot translational clinical pharmacology study of a brief (7 day) course of UFT, 300 mg/m²/day, in combination with leucovorin, 90 mg/day, in six patients with newly diagnosed advanced colorectal cancer.

Nicole Williams, MD
Latest Article

Triple-Negative Breast Cancer in the Post-Genomic Era

Clearly there is no single therapy for all patients with TNBC, given the molecular heterogeneity of this subtype. However, new insights from further genomic analysis of TNBC suggest approaches to rational clinical trial design, and patients will undoubtedly benefit as we define the most appropriate therapeutic targets in management of this aggressive disease.

Nicoletta Colombo, PhD
Latest Article

How to Address Sexual Problems in Female Cancer Patients

Sexual health is an important aspect of human life, and cancer does not (and should not) change that. Data suggest that issues related to sexual function are quite common among women treated for cancer. However, clinicians often spend little to no time on the topic.

Nicos Nicolaou, MD
Latest Article

Prevention and Management of Radiation Toxicity

The aim of radiation oncology is the achievement of uncomplicated locoregional control of malignancy by the use of radiation therapy (RT). Accomplishing this goal requires precise knowledge of tumoricidal and tolerance doses of the various normal tissues at risk within the RT field.

Niels Reinmuth, MD
Latest Article

Synopsis of Angiogenesis Inhibitors in Oncology

Angiogenesis is a dynamic process essential for primary tumor growth and metastases. New insights into the basic understanding of the biologic processes responsible for angiogenesis have led to the characterization of potential therapeutic targets. Several strategies for the development of antiangiogenic therapeutic modalities have been employed, including agents that (1) decrease the activity of specific angiogenic factors, (2) decrease the activity of endothelial survival factors, (3) increase the activity of naturally occurring antiangiogenic agents, or (4) indirectly downregulate angiogenic and survival factor activity.

Niharika B. Mettu, MD, PhD
Latest Article

Use of Molecular Biomarkers to Inform Adjuvant Therapy for Colon Cancer

In this review, we will discuss adjuvant chemotherapy in non-metastatic colon cancer, the existing prognostic and predictive molecular biomarkers in the field, and how to integrate these molecular biomarkers into the decision about whether to administer adjuvant therapy.

Nikhil C. Munshi, MD
Latest Article

Multiple Myeloma and Other Plasma Cell Dyscrasias

This management guide covers the symptoms, diagnosis, screening, staging, and treatment of multiple myeloma, smoldering myeloma, and other plasma cell dyscrasias.

Nikolaos Touroutoglou, MD, PhD
Latest Article

Neuroendocrine Tumors of the Gastrointestinal Tract

Neuroendocrine tumors manifest in the gastrointestinal tract mainly as carcinoid and pancreatic islet-cell tumors. They comprise an interesting group of rare neoplasms that are derived from neuroendocrine cells interspersed within the gastrointestinal system amd throughout the body. Neuroendocrine tumors are well known for producing various hormonal syndromes and for their indolent clinical course in most patients, although some of these tumors do not produce hormones of clinical significance. Patients may have symptoms for many years before the diagnosis is suspected and confirmed.

Nilo I. Rivera, MD
Latest Article

Opioids in Cancer Pain: Common Dosing Errors

Many individuals with advanced malignancy continue to sufferfrom pain and, consequently, impaired quality of life. The clinicalscenarios in advanced cancer pain are complex, and successful managementmay require a more sophisticated and individualized approachthan suggested by the World Health Organization guidelines.In patients referred to the Harry R. Horvitz Center for PalliativeMedicine in Cleveland, numerous commonly occurring errors inopioid use have been noted. This article describes these errors andoffers strategies with which to improve outcomes for patients sufferingwith cancer pain.

Nilofer Azad, MD
Latest Article

ACR Appropriateness Criteria® Borderline and Unresectable Pancreas Cancer

These guidelines review the use of radiation, chemotherapy, and surgery in borderline and unresectable pancreas cancer. Radiation technique, dose, and targets were evaluated, as was the recommended chemotherapy, administered either alone or concurrently with radiation. This report will aid clinicians in determining guidelines for the optimal treatment of borderline and unresectable pancreatic cancer.

Nilofer S. Azad, MD
Latest Article

The Utility of Molecular Testing in Colorectal Cancer: The Promise Needs Progress

Molecularly profiling colorectal cancer has opened many potential opportunities for the use of this information in therapeutic decision-making. However, at present, only RAS testing in the metastatic setting has a definitive place in the decision-making paradigm.

Nils O. Elander, MD, PhD
Latest Article

PARP Inhibition in Prostate Cancer: A Promising Approach

Having said that, PARP inhibition is one of the most promising approaches for “precision therapy” so far. Within the next few years and with the help of ongoing clinical trials, we should have a better understanding of whether or not the high expectations raised will be translated into clinical reality.

Nilton Xavier, MD
Latest Article

A Phase II Study of Doxorubicin/Paclitaxel Plus G-CSF for Metastatic Breast Cancer

This phase II trial was conducted to evaluate the percentage of objective responses and the toxicity profile of combination doxorubicin (Adriamycin) and paclitaxel (Taxol) with granulocyte colony-stimulating factor as first-line

Nina A. Mayr, MD
Latest Article

ACR Appropriateness Criteria® Management of Vaginal Cancer

This article represents the consensus opinion of an expert panel and may be used to inform clinical recommendations in vaginal cancer management.

Nina Bhardwaj, MD, PhD
Latest Article

Mutation-Derived Tumor Antigens: Novel Targets in Cancer Immunotherapy

Because of the abundance of promising preclinical and early-phase clinical data, mutation-derived tumor antigens an exciting new class of targets in cancer immunotherapy.

Nina Cohen, PharmD
Latest Article

Screening and Prevention of Hepatitis B Virus Reactivation During Chemotherapy

The incidence of both hepatitis B virus infection and cancer is common. The use of immunosuppressive therapy in patients with hepatitis B virus can result in reactivation of hepatitis B virus, which can, in turn, lead to significant morbidity and mortality.

Nina D. Wagner-Johnston, MD
Latest Article

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Nina N. Grenon, MS
Latest Article

The Evolving Care of Metastatic Colorectal Cancer

Progress in the care of mCRC has occurred relatively rapidly, but current methods of management have placed a significant economic burden on the healthcare system.

Nirali M. Patel, MD
Latest Article

Advanced Lab Testing in Lung Cancer

The most important marker to test is epidermal growth factor receptor (EGFR). EGFR is the second most common oncogenic driver in lung cancer, present in 15% of adenocarcinoma cases, but the most common mutation to be actionable with an approved drug.

Nirmal K. Veeramachaneni, MD
Latest Article

The Many Controversies of Stage IIIA/IIIB Lung Cancer

The first issue deserving comment is the heterogeneity of stage III disease. Stage IIIA N2 non–small-cell lung cancer (NSCLC) includes patients with at least one “incidental” N2 node detected at the time of surgical resection in patients who had a negative mediastinal evaluation (including mediastinoscopy) preoperatively. It also includes patients whose initial computed tomography (CT) and positron-emission tomography (PET) scans show multiple bulky (> 2 cm) nodes that are confirmed by either mediastinoscopy or endobronchial ultrasound-guided bronchoscopy.

Nirupa Raghunathan, MD
Latest Article

Obesity and Metabolic Disease After Childhood Cancer

In this review, childhood cancer survivor populations at risk for metabolic late effects, as well as mechanisms and ongoing intervention studies, will be detailed.

Nishan Tchekmedyian, MD
Latest Article

Propelling Immunotherapy Combinations Into the Clinic

This review summarizes promising new targets and immunotherapy combination strategies currently under clinical development.

Nitya Nathwani, MD
Latest Article

POINT: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma

Results of important studies addressing the optimal consolidation regimen and choice and duration of maintenance therapy are eagerly awaited, but it is evident that ASCT is imperative in the treatment of younger patients with multiple myeloma.

Niyati Bhagwati, MD
Latest Article

Incidence and Management of AIDS-Related Lymphoma

The article by Drs. Levine, Seneviratne, and Tulpule is an excellent review of the available literature on the incidence and treatment of lymphoma related to the acquired immunodeficiency syndrome (AIDS).

Niyati Nadkarni, MD
Latest Article

Cancer Management Chapter 17: Cervical cancer

Of the predominant gynecologic cancers, cancer of the uterine cervix is the least common, with only 11,270 new cases anticipated in the United States in 2009. Nevertheless, approximately 4,070 women die of cancer of the uterine cervix annually in the United States.

Noah A. Goldman, MD
Latest Article

Prophylactic Surgery in Hereditary Breast/Ovarian Cancer Syndrome

Drs. Levine and Gemignanihave provided a comprehensivereview of the literatureregarding the management of patientswith hereditary breast/ovarian cancersyndrome. As noted, over 200,000new cases of breast cancer and 25,000new cases of ovarian cancer are estimatedfor 2003.[1] Only a small portionof these cases will be hereditary;however, these are the cases that maybenefit from preventive measures. Thepotential for risk-reducing strategiesin these patients has become a criticalissue over the past several years. Thisreview highlights the salient featuresof identifying “at-risk” patients, aswell as the benefits and limitations ofsurgical prophylaxis.
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us